BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28753070)

  • 21. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
    Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
    Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
    Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
    Duijvestijn YC; Mourdi N; Smucny J; Pons G; Chalumeau M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD003124. PubMed ID: 19160217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
    Chalumeau M; Duijvestijn YC
    Cochrane Database Syst Rev; 2013 May; (5):CD003124. PubMed ID: 23728642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of exacerbations of COPD with pharmacotherapy.
    Miravitlles M
    Eur Respir Rev; 2010 Jun; 19(116):119-26. PubMed ID: 20956180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucoactive therapy in COPD.
    Decramer M; Janssens W
    Eur Respir Rev; 2010 Jun; 19(116):134-40. PubMed ID: 20956182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
    Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
    Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
    Poole PJ; Black PN
    Cochrane Database Syst Rev; 2003; (2):CD001287. PubMed ID: 12804402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
    Moretti M; Fagnani S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbocisteine for acute exacerbations of COPD.
    Waller P; Suissa S
    Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
    [No Abstract]   [Full Text] [Related]  

  • 34. A PEACE-ful solution to COPD exacerbations?
    Albert P; Calverley P
    Lancet; 2008 Jun; 371(9629):1975-6. PubMed ID: 18555897
    [No Abstract]   [Full Text] [Related]  

  • 35. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
    Poole PJ; Black PN
    Cochrane Database Syst Rev; 2000; (2):CD001287. PubMed ID: 10796634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents.
    Poole PJ; Black PN
    Am J Respir Med; 2003; 2(5):367-70. PubMed ID: 14719989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbocisteine for acute exacerbations of COPD.
    Mohapatra PR; Aggarwal D
    Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
    [No Abstract]   [Full Text] [Related]  

  • 38. Prediction and prevention of exacerbations and mortality in patients with COPD.
    Kostikas K; Clemens A; Patalano F
    Expert Rev Respir Med; 2016 Jul; 10(7):739-53. PubMed ID: 27135786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis.
    Papadopoulou E; Hansel J; Lazar Z; Kostikas K; Tryfon S; Vestbo J; Mathioudakis AG
    Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36697209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
    Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
    Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.